Moderna's mRNA melanoma vaccine shows promising Phase 3 trial results

Moderna announced promising results from Phase 3 clinical trials of a personalized mRNA vaccine for patients with advanced melanoma, one of the most aggressive forms of skin cancer. The company said the results represent a potential breakthrough for patients awaiting effective treatment options. Detailed efficacy figures were not disclosed in the announcement.